Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry.

Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry.

Br J Dermatol. 2017 May 12;:

Authors: Gisondi P, Bianchi L, Conti A, Dapavo P, Malagoli P, Piaserico S, Savoia F, Prignano F, Girolomoni G

Abstract
Infliximab is a chimeric human-murine monoclonal antibody that is very effective in chronic plaque psoriasis reaching a Psoriasis Area and Severity Index (PASI) 75 response in 80.4% of patients at week 10.(1) The more common adverse events include infusion reactions and upper respiratory tract infections.(2) The European Medicines Agency has approved the use of infliximab biosimilar CT-P13 for psoriasis by extrapolating efficacy from studies in rheumatoid arthritis and ankylosing spondilytis.(3,4) This article is protected by copyright. All rights reserved.

PMID: 28498543 [PubMed - as supplied by publisher]

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rbc0AT
via IFTTT